Table III.
Univariate analysis of locoregional control duration.
Univariate analysis | ||
---|---|---|
Factor | Hazard ratio (95% CI) | P-value |
Age (≥62 years vs. <62 years) | 0.630 (0.105–3.792) | 0.614 |
Concurrent chemotherapy (no vs. yes) | 0.321 (0.053–1.935) | 0.215 |
FIGO stage (I+II vs. III+IV) | 2.104 (0.350–12.638) | 0.416 |
PeLN (positive vs. negative) | 1.403 (0.233–8.457) | 0.711 |
PALN (positive vs. negative) | 0.126 (0.021–0.757) | 0.024 |
CD8+ TILs (pre-RT) (low vs. high) | 0.337 (0.037–3.053) | 0.334 |
CD8+ TILs (post-10 Gy) (low vs. high) | 0.187 (0.021–1.703) | 0.137 |
PeLN, lymph node metastasis in pelvis; PALN, para-aortic lymph node metastasis; RT, radiotherapy; TIL, tumor-infiltrating lymphocyte; FIGO, International Federation of Gynecology and Obstetrics.